Agenus to Report Third Quarter 2015 Financial Results on October 27, 2015; Conference Call to Follow
October 20 2015 - 7:00AM
Business Wire
Agenus Inc. (NASDAQ: AGEN), an immunology company discovering
and developing innovative treatments for cancers and other
diseases, will release its third quarter 2015 financial results
before the market opens on Tuesday, October 27, 2015. Agenus
executives will host a conference call at 11:00 a.m. Eastern Time
the same day.
To access the live call, dial 1-888-799-5016 (U.S.) or
1-704-908-0465 (international) and refer to conference ID number
63478685. The call will also be webcast and will be accessible from
the company’s website at www.agenusbio.com/webcast/. A replay will
be available on the company’s website approximately two hours after
the call and will remain available for 60 days. The replay number
is 1-855-859-2056 (U.S.) 1-404-537-3406 (international), conference
ID number 63478685.
About Agenus
Agenus is an immunology company engaged in the discovery and
development of novel checkpoint modulators, vaccines and adjuvants
to treat cancer and other diseases. Using its proprietary platforms
Retrocyte Display™ and SECANT®, the Company is discovering and
developing novel antibodies to target GITR, OX40, CTLA-4, LAG-3,
TIM-3, PD-1, CEACAM1 and other undisclosed checkpoints in partnered
and internal programs. Agenus’ heat shock protein vaccine,
Prophage, has successfully completed Phase 2 studies in newly
diagnosed glioblastoma multiforme. The Company’s QS-21 Stimulon®
adjuvant is partnered with GlaxoSmithKline and Janssen Sciences
Ireland UC. For more information, please visit www.agenusbio.com,
or follow the company on Twitter @Agenus_Bio; information that may
be important to investors will be routinely posted in these
locations.
Forward-Looking Statements
This press release contains forward-looking statements that are
made pursuant to the safe harbor provisions of the federal
securities laws, including statements regarding Agenus’ anticipated
timing for releasing its third quarter 2015 financial results.
These forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially.
These risks and uncertainties include, among others, the factors
described under the Risk Factors section of Agenus’ Form 10-Q filed
with the Securities and Exchange Commission on August 3, 2015.
Agenus cautions investors not to place considerable reliance on the
forward-looking statements contained in this release. These
statements speak only as of the date of this press release, and
Agenus undertakes no obligation to update or revise the statements,
other than to the extent required by law. All forward-looking
statements are expressly qualified in their entirety by this
cautionary statement.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151020005345/en/
Agenus Inc.Michelle Linn, 774-696-3803Agenus
Inc.michelle.linn@agenusbio.comorMedia:BMC
CommunicationsBrad Miles,
646-513-3125bmiles@bmccommunications.comorInvestors:Argot
PartnersAndrea Rabney/Jamie Maarten,
212-600-1902andrea@argotpartners.comjamie@argotpartners.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024